Physician profile
Barbara Jean Epps
NPI 1700391430
$1,147.27
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $458 · 2022: $387 · 2023: $185 · 2024: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $218 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $217.63 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $385.93 | 2021-2023 | |
| Novo Nordisk INC | $105.70 | 2021-2023 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $84.99 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $68.12 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $66.63 | 2022 | |
| Merck Sharp & Dohme LLC | $53.39 | 2021-2022 | |
| Lilly USA, LLC | $47.62 | 2021-2023 | Mounjaro |
| Edwards Lifesciences Corporation | $39.96 | 2022-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Bayer Healthcare Pharmaceuticals INC. | $39.47 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $34.75 | 2023-2024 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $29.72 | 2022-2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.08 | 2023 | Jardiance, Synjardy |
| Amgen INC. | $28.99 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $25.55 | 2021-2022 | |
| Exact Sciences Corporation | $21.76 | 2023 | Cologuard Collection Kit |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $19.25 | 2024 | |
| Sanofi-Aventis U.S. LLC | $17.18 | 2023 | |
| Esperion Therapeutics, INC. | $16.42 | 2022 | |
| Seqirus USA INC | $13.00 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Pfizer INC. | $11.43 | 2021 | |
| Cequr Corporation | $8.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Epps listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.